Commentary on: Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP–parkinsonism, by D. Williams, R. de Silva, D. Paviour, et al . ( Brain -2004-01045.R1)

By Burn David J.  

Brain, Vol. 128, Iss. 6, 2005-06 ,pp. : 1235-1236

Oxford University Press

Access to resources Recommend Favorite

Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome

By Williams David R.  

Brain, Vol. 130, Iss. 6, 2007-06 ,pp. : 1566-1576

Oxford University Press

Access to resources Recommend Favorite

The prevalence of progressive supranuclear palsy (Steele–Richardson–Olszewski syndrome) in the UK

By Nath U.  

Brain, Vol. 124, Iss. 7, 2001-07 ,pp. : 1438-1449

Oxford University Press

Access to resources Recommend Favorite

Fluvoxamine for the treatment of depression and parkinsonism in progressive supranuclear palsy

By Miyaoka Tsuyoshi   Seno Haruo   Inagaki Takuji   Horiguchi Jun  

International Journal of Psychiatry in Clinical Practice, Vol. 6, Iss. 1, 2002-03 ,pp. : 45-47

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Magnetic resonance imaging lesion pattern in Guadeloupean parkinsonism is distinct from progressive supranuclear palsy

By Lehricy Stphane  

Brain, Vol. 133, Iss. 8, 2010-08 ,pp. : 2410-2425

Oxford University Press

Access to resources Recommend Favorite